Karyopharm Therapeutics Stock News

Although it met its primary endpoint, the results of a late-stage trial of Karyopharm''s Xpovio (selinexor) in endometrial cancer are being viewed as a disappointment.

Karyopharm Therapeutics (KPTI) CEO, Richard Paulson on Q 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.

Karyopharm Therapeutics press release (KPTI): Q4 EPS of $0.46 may not be comparable to consensus of -$0.42.Revenue of $126.2M (+259.5% Y/Y) beats by $94.28M.Based on its current

Companies Reporting Before The Bell Pfizer (NYSE: PFE ) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. Karyopharm Therapeutics (NASDAQ: KPTI ) is likely to report quarterly loss at $0.49 per share on revenue of $50.49 million. Thomson Reuters (NYSE: TRI ) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.68 billion. Beasley Broadcast Group (NASDAQ: BBGI ) is likely to report quarterly earnings at $0.03 per share on revenue of $69.67 million. Willis Towers Watson (NASDAQ: WTW ) is projected to report quarterly earnings at $4.98 per share on revenue of $2.50 billion. Cenovus Energy (NYSE: CVE ) is expected to report quarterly earnings at $0.39 per share on revenue of $11.25 billion. Jacobs Engineering Group (NYSE: J ) is projected to report quarterly earnings at $1.58 per share on revenue of $3.51 billion. CTS (NYSE: CTS ) is estimated to report quarterly earnings at $0.47 per share on revenue of $122.96 million.

Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to announce Q4 earnings results on Tuesday, February 8th, before market open.The consensus EPS Estimate is -$0.42 (+28.8% Y/Y) and…

Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Karyopharm Therapeutics (KPTI) granted 15 newly-hired employees stock options to buy a total of 124.5K common shares.The stock options were granted as inducements material and

The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.

The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.

NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Pauls

Karyopharm Therapeutics <> expects net product revenues of XPOVIO to be ~$29.7M for Q4 and ~$98.3M for FY21."For 2022, we are focused on making significant advances across

Karyopharm Therapeutics Inc (KPTI) shares closed today 10.4% higher than it did at the end of yesterday. The stock is currently flat year-to-date, down 58.5% over the past 12 months, and down 31.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $7.27 and as low as $6.41 this week.Shares closed 60.6% below its 52-week high and 60.6% above its 52-week low.Trading volume this week was 3.6% lower than the 10-day average and 44.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date is the same as the peer average. The company's stock price performance over the past 12 months lags the peer average by -1183.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.